Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: Comparison with typical and atypical conventional antipsychotics

Behavioural Pharmacology

Volumn 18, Issue 2, 2007, Pages 103-118

  Bardin, Laurent ^a   Auclair, Agnès ^a   Kleven, Mark S ^a,b   Prinssen, Eric P M ^a,c   Koek, Wouter ^a,d   Newman Tancredi, Adrian ^a   Depoortère, Ronan ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Yaupon Therapeutics Inc   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

5 HT1A receptors; Antipsychotics; Catalepsy; Conditioned avoidance response; D amphetamine; Dopamine D2 receptors; Methylphenidate; Rat

Indexed keywords

3 EXO 8 BENZOYL N [(7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL)METHYL] 8 AZABICYCLO[3.2.1]OCTANE 3 METHANAMINE; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 8 [4 [3 (5 FLUORO 1H INDOL 3 YL)PROPYL] 1 PIPERAZINYL] 2 METHYL 1,4 BENZOXAZIN 3(4H) ONE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; HALOPERIDOL; KETAMINE; METHYLPHENIDATE; OLANZAPINE; RISPERIDONE; SARIZOTAN; SEROTONIN 1A RECEPTOR; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; HYPERACTIVITY; MALE; NONHUMAN; PSYCHOSIS; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CATALEPSY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; EXCITATORY AMINO ACID ANTAGONISTS; INJECTIONS, INTRAPERITONEAL; KETAMINE; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2;

EID: 33947148162     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3280ae6c96     Document Type: Article

References (75)

1. Arnt J (1982). Pharmacological specificity of conditioned avoidance response inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321-329.
2. Arnt J (1995). Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62.
3. 1A receptor agonist properties of the antipsychotic nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334:141-147.
4. 2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 373:441-450.
5. 1A affinity in rodent models of cognitive flexibility and sensory gating: II) the reversal learning task and PPI of the startle reflex. Int J Neuropsychopharmacol 9 (Suppl. 1):P01.167.
6. 1A receptor by clozapine measured using PET scanning. J Psychopharmacol 14:PG20.
7. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37-46.
8. Bantick RA, Montgomery AJ, Bench CJ, Choudhry T, Malek N, McKenna PJ, et al. (2004). A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol 18: 346-354.
9. Baptista T, Kin NM, Beaulieu S, De Baptista EA (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219.
10. 1A agonist properties. Neuropsychopharmacology 31:1869-1879.
11. 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 111:113-126.
12. Bibbiani F, Oh JD, Chase TN (2001). Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829-1834.
13. 1A agonists in the treatment of depression?. Biol Psychiatry 53:193-203.
14. Brar JS, Chengappa KN, Parepally H, Sandman AR, Kreinbrook SB, Sheth SA, Ganguli R (1997). The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann Clin Psychiatry 9:227-234.
15. Broekkamp CL, Oosterloo SK, Berendsen HH, Van Delft AM (1988). Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338:191-195.
16. 2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534:63-70.
17. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A (2002). Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 159:1035-1043.
18. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, et al. (2005). Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N- desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278-1287.
19. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, Mc-kinzie DL (2003). Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1125-1143.
20. 1A receptors by clozapine in the primate brain: a PET study. Psychopharmacol 166: 234-240.
21. Christoffersen CL, Meltzer LT (1998). Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino) tetralin and its enantiomers. Neuropsychopharmacology 18:399-402.
22. 1A receptor agonist. I: neurochemical and electrophysiological profile. Neuropsychopharmacology 28:2064-2076.
23. 2 receptors: G-protein activation and prolactin release. Eur J Pharmacol 535:135-144.
24. Cussac D, Duqueyroix D, Newman-Tancredi A, Millan MJ (2002). Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h) serotonin 5-HT1A receptors. Psychopharmacology 162:168-177.
25. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564.
26. 1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28:1889-1902.
27. 4 partial agonist: II) profile in tests predictive of activity against positive, negative signs and cognitive deficits of schizophrenia. Eur Neuropsychopharmacology (Suppl 16) S434. P3d009.
28. 4 partial agonist properties: II) Activity in models of positive symptoms of schizophrenia. Br J Pharmacol (in press).
29. 4 partial agonist properties: III) Activity in models of cognition and negative symptoms. Br J Pharmacol (in press).
30. Fitton A, Heel RC (1990). Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722-747.
31. Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD (1980). An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of D-amphetamine and apomorphine. Psychopharmacology 69:253-259.
32. Gleason SD, Shannon HE (1997). Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79-84.
33. 1A receptor agonist: in vitro and in vivo neuropharmacology. Eur Neuropsychopharmacol 12 (Suppl. 3):P2.053.
34. Hubert JJ (1984.) Bioassay. 2nd ed. Dubuque, Iowa: Kendall/Hunt Publishing Co.
35. 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858:252-263.
36. Invernizzi RW, Cervo L, Samanin R (1988). 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518.
37. Kallen A, Larsson P (1999). Dose response studies: how do we make them conclusive? Stat Med 18:629-641.
38. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, et al. (2002). Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder - implications for psychopharmacology. World J Biol Psychiatry 3:133-146.
39. 2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 313:25-34.
40. 1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49:135-143.
41. Koek W, Colpaert FC (1993). Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptics. J Pharmacol Exp Ther 267:181-191.
42. Kuzhikandathil EV, Sayed N, Pasuit JB, Bartoszyk GD (2004). Differential effects of sarizotan on dopamine receptor function. Soc Neurosci. [Abstract 163.6].
43. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
44. Lieberman JA, Johns C, Cooper T, Pollack S, Kane J (1989). Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 99:54-59.
45. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
46. Martin P, Waters N, Carlsson A, Carlsson ML (1997). The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104:561-564.
47. Meltzer HY (1995). Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press Ltd; pp. 1277-1288.
48. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
49. 1A receptors. J Pharmacol Exp Ther 295:853-861.
50. Millan MJ (2005). N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179:30-53.
51. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356-1373.
52. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J, et al. (1999). Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine vs. amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419-4432.
53. Moore KE (1978.) Amphetamines: biochemical and behavioral actions in animals. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of psychopharmacology: stimulants. New York: Plenum Press; pp. 41-98.
54. Mueser KT, McGurk SR (2004). Schizophrenia. Lancet 363:2063-2072.
55. 35S]GTPγS binding study. Eur J. Pharmacol 355:245-256.
56. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8:341-356.
57. 4 partial agonist properties: I. in vitro, neurochemical and neuroendocrine profiles. Int J Neuropsychopharmacol 9(Suppl) P01.164.
58. 4 partial agonist properties: I) in vitro, neurochemical and neuroendocrine profiles. Br J Pharmacol (in press).
59. 1A receptor agonist properties. Eur J Pharmacol 356:189-192.
60. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144:20-29.
61. 1A receptors. Eur J Pharmacol 395:143-147.
62. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453:217-221.
63. Roth BL, Hanizavareh SM, Blum AE (2004). Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17-24.
64. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. (1995). Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113.
65. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, et al. (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725.
66. 1A agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868.
67. Tallarida RJ, Murray RG (1987). Manual of pharmacological calculations with computer programs. New York: Springer Verlag Press.
68. Tschanz JT, Rebec GV (1988). Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol Biochem Behav 31:519-522.
69. Waddington JL (1986). Psychopharmacological studies in rodents: strereotaxic intracerebral injections and behavioral assessment. In: Joseph MH, Waddington JL, editors. Working methods in neuropsychopharmacology. Manchester University Press; pp. 1-40.
70. Wadenberg ML, Hicks PB (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
71. 2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633-641.
72. Wolf W (2003). DU127090. Curr Opin Investig Drugs 4:72-76.
73. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472.
74. Yoshida K, Sugita T, Higuchi H, Hishikawa Y (1998). Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13:421-422.
75. Zhang W, Bymaster FP (1999). The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 141:267-278.